GlassScriptPhysician profile
Kaunteya Reddy
NPI 1801129341
$3,033.87
in general payments reported to CMS, 2019-2025
21 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $103 · 2021: $298 · 2022: $325 · 2023: $771 · 2024: $762 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $582.27 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $382.93 | 2021-2025 | Epclusa |
| Abbvie INC. | $336.20 | 2020-2025 | |
| Janssen Biotech, INC. | $330.95 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $325.37 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.62 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $149.69 | 2024 | |
| Pentax of America, INC. | $146.42 | 2022-2023 | Imagina |
| Takeda Pharmaceuticals U.S.A., INC. | $109.23 | 2019-2023 | Entyvio |
| Allergan, INC. | $96.24 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $63.20 | 2019-2023 | Rebyota |
| Exact Sciences Corporation | $55.34 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $54.48 | 2021 | |
| Pfizer INC. | $50.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.08 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $35.71 | 2021 | |
| Amgen INC. | $22.17 | 2020 | |
| Novo Nordisk INC | $21.63 | 2025 | Wegovy |
| Stryker Corporation | $15.32 | 2025 | Actishield |
| Mallinckrodt Hospital Products INC. | $15.10 | 2023 | Terlivaz |
| Celgene Corporation | $13.70 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaunteya Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.